Xanomeline

Drug Profile

Xanomeline

Alternative Names: LY 246708; Memcor; NNC 110232

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Eli Lilly
  • Class Antidementias
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 15 Dec 2016 Xanomeline licensed to Karuna Pharmaceuticals worldwide before December 2016
  • 21 Dec 1998 Discontinued-II for Alzheimer's disease in USA (Transdermal)
  • 21 Dec 1998 Discontinued-III for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top